Workflow
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million
Apogee TherapeuticsApogee Therapeutics(US:APGE) Newsfilterยท2024-03-12 20:01

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing differentiated biologics for treating atopic dermatitis, chronic obstructive pulmonary disease, asthma, and other inflammatory and immunology indications [5] - The company aims to address high unmet medical needs by utilizing advanced antibody engineering to optimize therapeutic properties [5] Recent Financial Activity - Apogee announced the closing of an upsized public offering of 7,790,321 shares of common stock at a public offering price of $62.00 per share, resulting in gross proceeds of approximately $483.0 million before expenses [1] - The offering included the full exercise of the underwriters' option to purchase an additional 1,016,128 shares [1] Underwriters - Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen, and Stifel acted as joint book-running managers for the offering [2]